Piper Sandler Rates Abbott Laboratories (ABT) buy
Piper Sandler reiterates its buy rating on Abbott Laboratories with a price target of $115, reflecting confidence in the stock’s potential upside.
Reviewed by automated data checks against the source data. How we make and check alerts
Piper Sandler rated Abbott Laboratories ($ABT) "buy" with a $115 price target on June 22, 2026.
Since the rating, $ABT is up 5.6% after 1 week, up 15.3% after 1 month and up 21.0% to date (from the $86.67 close on Jun 22, 2026).
ABT
Abbott Laboratories
Key Points
- On June 22, 2026, Piper Sandler reiterated its buy rating on Abbott Laboratories (NYSE: ABT) with a price target of $115.00.
- The stock is currently trading at $91.38, which suggests a potential upside of about 25.8% to reach the new target.
- Analysts have a strong consensus on Abbott, with a mean price target of $120.71 from 26 opinions.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Piper Sandler's Updated Rating
On June 22, 2026, Piper Sandler reiterated its buy rating on Abbott Laboratories (NYSE: ABT) and set a price target of $115. This rating reflects the firm's confidence in the stock's potential to appreciate in value. The current trading price of $91.38 indicates that there is a notable upside opportunity for investors.
Piper Sandler vs. the S&P 500
Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
Analysts have shown strong support for Abbott Laboratories recently. The average price target among 26 analysts is $120.71, suggesting that many believe the stock could rise significantly from its current price. This consensus includes recent ratings from TD Cowen, which also maintains a buy rating with a target of $135, and Barclays, which recently initiated coverage with an overweight rating and a target of $120.
Stock Performance Overview
Abbott's stock is currently trading at $91.38, well below its 52-week high of $132.03. This price level may attract attention as investors consider the gap between the current trading price and the new target set by Piper Sandler. The stock has not performed as strongly in recent months, trading near its 50-day moving average of $105.93, which could signal a buying opportunity for those looking to invest.
$ABT price target
Abbott Laboratories daily closes and this analyst's $115 target. Not advice.
Recent Earnings and Financials
Abbott Laboratories reported revenue of approximately $46.58 billion, with a revenue growth of 13% year-over-year. The company has a P/E ratio of about 33.77, reflecting its growth potential in the healthcare sector. The next earnings report is scheduled for October 21, 2026, which will provide further insights into the company's financial health.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
What Abbott Laboratories Does
Abbott Laboratories develops and sells a variety of healthcare products, including medical devices and nutritional products. Its diverse portfolio positions it well within the healthcare industry, making it a key player to watch as it navigates market challenges and opportunities.
What’s Next for Abbott?
Investors will be looking forward to Abbott's next earnings report on October 21, 2026, for updated insights into its performance. The reiterated buy rating from Piper Sandler highlights ongoing confidence in the company, while the 13F filings will provide further insights into institutional sentiment in the coming months.
Related Filing Alerts
Source: Piper Sandler's rating change on $ABT (Jun 22, 2026). Written by software, not financial advice. How we make alerts